If you just read the New York Post’s review of Hims Testosterone Rx, here’s the short answer: it isn’t testosterone. It’s a prescription tablet of enclomiphene, which Hims says is compounded and not FDA-approved, and Hims’s clinician says it works by encouraging the pituitary to send stronger signals so the testicles make more of their own testosterone. The reviewer took it for eight months, and the Post published his results on November 17, 2026. Below you’ll find what the pill is, what it costs, what one man’s bloodwork looked like, what the 2016 trial found, and the questions to settle with a urologist before you decide anything.
Affiliate disclosure: Note that this page uses affiliate links. The editors may earn a commission if you buy through them. It does not add to the price you pay.
Quick facts as of 2026-11-17
| Fact | Detail |
|---|---|
| What the pill contains | Enclomiphene. The Post says there is “no testosterone in the bottle.” |
| Approval status | Compounded and not FDA-approved, according to Hims’s app as the Post reports it. |
| What Hims says it does | Encourages the pituitary to send stronger signals so the testicles make more of their own testosterone, per Dr. Peter Stahl, Hims’s senior vice president of sexual health. |
| Starting price | $99 a month on a 10-month plan, with $990 paid upfront, as the Post reported it. |
| Who Hims says it suits | A man with symptoms and confirmed low testosterone whose body can still make its own, especially a man protecting fertility. |
| Main research | Kim et al., BJU International, 2016: two 16-week phase III trials. |
What happened: the Post’s eight-month review
The New York Post published a first-person product review on November 17, 2026. The reviewer is a man in his 40s who took Hims Testosterone Rx for eight months. Hims’s clinician, Dr. Peter Stahl, is quoted in the piece. The reviewer’s own verdict is that it’s worth it for a man whose numbers are drifting. He reported lifting and recovery “a bit better,” said he was still tired, and said he had zero side effects. You can read the whole thing in the New York Post’s eight-month review.
What is Hims Testosterone Rx, and how is it meant to work?
Hims Testosterone Rx is a prescription tablet of enclomiphene, and the Post says there is no testosterone in the bottle. Hims says in its app that the pill is compounded and not FDA-approved. Hims’s FAQ says the FDA turned down enclomiphene, sold then as Androxal by Repros Therapeutics, in December 2015. The FAQ says the agency cited trials not built to prove clinical benefit, and enclomiphene is still not approved.
Dr. Stahl describes the mechanism this way: enclomiphene encourages the pituitary to send stronger signals, so the testicles make more of their own testosterone. Hims’s Hims’s September 2025 launch release says enclomiphene “restores natural testosterone production, without compromising fertility.” Those are the company’s words about its own product.
If you want background on how that signalling works, our guide to testosterone production covers the pituitary, the testes and age-related decline.
Does Hims have TRT?
The sources disagree, and the dates matter. The Post says Hims started offering real testosterone replacement after its reviewer began, and its price table lists injectable testosterone cypionate from $79 a month. The Post also reports that Hims’s FAQ lists Kyzatrex, an oral testosterone the FAQ says was FDA-approved in July 2022, and generic testosterone cypionate injections.
A comparison published October 11, 2026 by Anabolic Insights quotes a Hims FAQ that says Hims “does not currently offer access to TRT injections.” That comparison lists injectable and oral testosterone as “Coming in 2026.” Hims’s own September 2025 release said it would bring Kyzatrex and injectable testosterone in 2026.
Which of those accounts is current is the question to put to Hims directly before you rely on either one.
Does enclomiphene raise testosterone?
In the trial the Post points to, yes. Kim and colleagues reported two phase III studies in BJU International in 2016 (Kim 2016 trial on PubMed). The studies, ZA-304 and ZA-305, were randomized, double-blind and placebo-controlled. They studied overweight men aged 18 to 60 with secondary hypogonadism, defined as early morning total testosterone of 300 ng/dL or lower with low or normal LH. Each ran 16 weeks.
Testosterone rose in all treatment groups. The authors concluded that enclomiphene “consistently increased serum TT, LH and FSH,” restoring normal testosterone while maintaining sperm concentrations. Enclomiphene kept sperm concentration in the normal range. The testosterone gel group had a marked fall in sperm production.
The trial measured hormone levels and sperm counts over 16 weeks, not symptoms or long-term safety. Dr. Stahl says the evidence on years of use is limited: “Not as much as we’d like.” He adds that “the largest controlled enclomiphene trials lasted 16 weeks.”
What did the reviewer’s bloodwork show?
These are one man’s numbers, as the Post reported them. He tested at home with a kit that uses two arm-worn collection devices, which he mailed back. Results appeared in the app within a couple of days, and a provider signed off before the prescription. All care runs through app messaging, and the Post says no video or phone visit was offered.
| Date | Testosterone (ng/dL) | Dosing at the time |
|---|---|---|
| March 5 | 430 (lab range 249 to 836) | Before the prescription, which was ordered March 11 |
| June 1 | 1,273 | One pill daily |
| Sept. 20 | Over 1,500 | Paused for 18 days |
| Oct. 11 | 694 | Every other day |
His hematocrit was 37.9%, below the lab floor of 40.1%, and it was flagged to his primary care doctor. Dr. Stahl says overshoot is “not the most common pattern” but does happen.
How much does Hims Testosterone Rx cost?
These are the prices the Post reported on November 17, 2026.
| Hims option | Price, as the Post reported it |
|---|---|
| Hims Testosterone Rx (enclomiphene) | $99 a month on a 10-month plan, starting price, with $990 paid upfront |
| Testosterone Rx+ (enclomiphene, tadalafil and supplements) | From $49 a month |
| Injectable TRT (testosterone cypionate) | From $79 a month |
The Post’s reviewer paid the $990 upfront for his 10 months. Hims’s January 2026 price guide lists the initial lab kit at $94, as Anabolic Insights reports on October 11, 2026, and T-Compare lists the same charge when it checked on November 2, 2026. Anabolic Insights also reports that Hims “doesn’t take FSA or HSA plans as payment at this time.”
The refund terms are the part to read closely. Anabolic Insights reports that Hims requires a subscription for prescription products, that you cancel at least 48 hours before your next order, and that Hims says refunds aren’t assured once the pharmacy has processed an order. T-Compare, checking Hims’s terms on November 2, 2026, says plans end at the close of the prepaid period with no partial refunds.
What labs and monitoring does it involve?
Dr. Stahl describes a standard schedule: bloodwork at the start, again within the first couple of months, then at least once a year. He says hematocrit is monitored, and PSA is monitored for older men. The Post says the reviewer had four tests across eight months.
How is it different from FDA-approved testosterone?
The FDA’s pages cover approved testosterone products, not compounded enclomiphene. The FDA’s testosterone information page and the FDA’s 2025 class-wide labeling changes set out what those approved products are for and what the agency has said about their safety.
| Topic | What FDA’s testosterone pages say |
|---|---|
| Who approved products are for | Men who lack or have low testosterone together with an associated medical condition, such as testicular failure from genetic problems or chemotherapy, or pituitary or hypothalamic problems. |
| Low testosterone alone | The June 23, 2026 page says none are approved for men with low testosterone without an associated medical condition. |
| Approved forms | Topical gel, transdermal patch, buccal system and injection. The 2025 page adds oral. |
| Cardiovascular trial | In TRAVERSE, more than 5,200 men on AndroGel 1.62% had a major adverse cardiovascular event at 7.0%, versus 7.3% on placebo. FDA found no new safety signal or trend in adverse cardiovascular outcomes. |
| Blood pressure | The 2025 labeling action confirmed an increase in blood pressure with all testosterone products. Labels get a new or updated blood pressure warning, and boxed-warning language on cardiovascular outcomes is removed. |
In June 2026, FDA requested prescribing-information updates for testosterone products, including removing the limitation of use on age-related hypogonadism.
Who is it for, and who should skip it?
Dr. Stahl describes the target as “a man with symptoms and confirmed low testosterone” whose body can still make its own, especially a man protecting fertility. He lists these as reasons to skip it:
- a higher risk of blood clots
- significant liver disease
- a history of prostate or male breast cancer
Hims lists headaches, nausea, hot flashes, mood changes and, rarely, vision changes as possible side effects. The reviewer reported none.
Common mix-ups: enclomiphene, Clomid and testosterone
| Name | What it is |
|---|---|
| Hims Testosterone Rx | An enclomiphene tablet with no testosterone in it, per the Post. |
| Enclomiphene | One of the two parts of clomiphene, the drug sold as Clomid. T-Compare notes it is not sold as its own FDA-approved drug. |
| Testosterone Rx+ | Hims’s combination of enclomiphene, tadalafil and supplements, per the Post. |
| Injectable testosterone (testosterone cypionate) | Replaces testosterone rather than prompting your body to make more. T-Compare says injectable testosterone can lower sperm production. |
| Kyzatrex | An oral testosterone that the Post says the FDA approved in July 2022. |
Key dates
| Date | What happened |
|---|---|
| December 2015 | FDA turned down enclomiphene, sold then as Androxal, per Hims’s FAQ as the Post reports it. |
| February 28, 2025 | FDA issued class-wide labeling changes for testosterone products. |
| September 10, 2025 | Hims announced a men’s health category, tailored doses of compounded enclomiphene, and plans for Kyzatrex and injectable testosterone in 2026. |
| March 5 | First test in the Post’s review: 430 ng/dL. |
| March 11 | Prescription ordered. |
| March 16 | Bottle arrived. |
| June 1 | Test: 1,273 ng/dL on one pill daily. |
| June 2026 | FDA requested prescribing-information updates for testosterone products. Its page is dated June 23, 2026. |
| September 20 | Test: over 1,500 ng/dL. Treatment paused for 18 days. |
| October 11 | Test: 694 ng/dL on every-other-day dosing. |
| October 11, 2026 | Anabolic Insights publishes a comparison quoting Hims’s FAQ on TRT injections. |
| November 17, 2026 | The New York Post publishes its first-person review. |
Questions to settle with a urologist
A urologist, or another prescriber who handles testosterone, is the person to settle these with. Bring these questions:
- Do my symptoms and my early-morning testosterone results point to low testosterone? T-Compare summarizes the American Urological Association guideline as calling for symptoms plus two early-morning total testosterone tests below about 300 ng/dL.
- How does my fertility plan affect which option fits me?
- Do I have any of the conditions Hims lists as reasons to skip it?
- Which of my current medicines or supplements could interact with this? Our guide to testosterone booster drug interactions covers the supplement side of that question.
- What monitoring schedule would I follow, including hematocrit and PSA?
- Does an FDA-approved testosterone product or a compounded enclomiphene tablet fit my labs and history better?
By Prime Years Health Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.